Modulation of Serotonin in PAH
Mandy MacLean, University of Glasgow Scotland PVRI – Pulmonary Vascular Research Institute
Rodatristat Ethyl Publications
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Repeated Once or Twice Daily RVT-1201, a TPH Inhibitor for Treatment of PAH 1 October 2019 European Respiratory Society (ERS) International Congress; Madrid, Spain
Wring S, Rurka J, Crizer KR, Palacios M, Snyder M, Keller L, Evans P, Carpenter D
View Original Publication »
Translational Analysis of RVT-1201 Nonclinical and Clinical Pharmacokinetic and Pharmacodynamic Biomarker Data to Predict Clinical Dose of a Novel TPH Inhibitor for Treatment of Pulmonary Arterial Hypertension 2 February 2019 13th PVRI Annual World Congress on PVD; Barcelona, Spain.
Wring S, Alonso-Galicia M, Crizer KR, Gaukel E, Holman N, Pack T, Palacios M, Rurka J, Carpenter D, Rhodes M.
View Original Publication »
Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension J Pharmacol Exp Ther. 2017 Feb;360(2):267-279.
Aiello RJ, Bourassa PA, Zhang Q, Dubins J, Goldberg DR, De Lombaert S, Humbert M, Guignabert C, Cavasin MA, McKinsey TA, Paralkar V.
View Original Publication »
Tryptophan Hydroxylase (TPH) Platform Publications
The Serotonin Hypothesis of PAH – Reviews
Peripheral Serotonin Modulation with Tph1 Inhibitors
Tryptophan Hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension J Pharmacol Exp Ther. 2017 Feb;360(2):267-279.
Aiello RJ, Bourassa PA, Zhang Q, Dubins J, Goldberg DR, De Lombaert S, Humbert M, Guignabert C, Cavasin MA, McKinsey TA, Paralkar V.
View Original Publication »
Clinical Data Linking Serotonin to PAH
Appetite-suppressant drugs and the risk of primary pulmonary hypertension International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996 Aug 29;335(9):609-16.
Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Bégaud B.
View Original Publication »
Preclinical Data Linking Serotonin to PAH
Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression Am J Respir Crit Care Med. 2013 Jan 1;187(1):78-89.
Ciuclan L, Hussey MJ, Burton V, Good R, Duggan N, Beach S, Jones P, Fox R, Clay I, Bonneau O, Konstantinova I, Pearce A, Rowlands DJ, Jarai G, Westwick J, MacLean MR, Thomas M.
View Original Publication »
Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice Circulation. 2008 Jun 3;117(22):2928-37.
Dempsie Y, Morecroft I, Welsh DJ, MacRitchie NA, Herold N, Loughlin L, Nilsen M, Peacock AJ, Harmar A, Bader M, MacLean MR.
View Original Publication »
Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension Circ Res. 2006 May 26;98(10):1323-30.
Guignabert C, Izikki M, Tu LI, Li Z, Zadigue P, Barlier-Mur AM, Hanoun N, Rodman D, Hamon M, Adnot S, Eddahibi S.
View Original Publication »
Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia Circulation. 2006 Apr 18;113(15):1857-64.
Eddahibi S, Guignabert C, Barlier-Mur AM, Dewachter L, Fadel E, Dartevelle P, Humbert M, Simonneau G, Hanoun N, Saurini F, Hamon M, Adnot S.
View Original Publication »
Patient Engagement Publications